Allena Pharmaceuticals

The company's lead product candidate was reloxaliase, an oral enzyme therapeutic designed to treat hyperoxaluria, a metabolic condition characterized by high levels of urinary oxalate that often leads to kidney stones and chronic kidney disease. Reloxaliase worked by breaking down oxalate in the gastrointestinal tract to reduce its absorption into the body. Another significant product in their pipeline was ALLN-346, a urate-degrading enzyme for patients suffering from hyperuricemia and gout, particularly those with advanced chronic kidney disease. Allena had pursued a Biologics License Application (BLA) for reloxaliase under the FDA's accelerated approval pathway and had received Fast Track Designation for ALLN-346.

After its founding in 2011, Allena Pharmaceuticals went public with an initial public offering (IPO) on November 2, 2017, raising $80 million. Over its lifetime, the company raised a total of $222 million. However, the company faced significant challenges. On September 2, 2022, Allena Pharmaceuticals filed for Chapter 11 bankruptcy protection. This led to the termination of its CEO, Louis Brenner, and CFO, Richard D. Katz. Ultimately, the company's plan of liquidation was approved, and it went out of business effective June 20, 2023.